Business Context and Reporting Period
Company: Lyell Immunopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date: June 17, 2025
Subject: Announcement of new clinical data from the ongoing Phase 1/2 trial of LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate for large B-cell lymphoma (LBCL).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding clinical trial results and does not contain financial statements. The document does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The filing reports significant clinical efficacy and safety data for LYL314 as of the April 15, 2025 cutoff date, involving 51 CAR T-naive patients with relapsed and/or refractory (R/R) LBCL.
Efficacy Results (3L+ Setting)
- Population: 25 efficacy-evaluable patients (median follow-up: 9 months).
- Overall Response Rate (ORR): 88% (22/25 patients).
- Complete Response (CR): 72% (18/25 patients).
- Durability: 71% (10/14) of patients with CR remained in CR at ≥ 6 months.
Efficacy Results (2L Setting)
- Population: 11 efficacy-evaluable patients (median follow-up: 5 months).
- Overall Response Rate (ORR): 91% (10/11 patients).
- Complete Response (CR): 64% (7/11 patients).
- Durability: 100% (7/7) of patients with CR remained in CR at last assessment; 3/3 at ≥ 6 months.
- Primary Refractory Subgroup: 70% (7/10) achieved CR despite high-risk features (91% primary refractory, 64% Stage IV, median age 73).
Safety Profile
- Cytokine Release Syndrome (CRS): No Grade ≥ 3 events. Grade 1: 22%; Grade 2: 35%.
- Neurotoxicity (ICANS): Grade 1: 6%; Grade 2: 2%; Grade ≥ 3: 14%. Median time to complete resolution was 5 days.
- Mortality: No deaths related to LYL314 administration.
- Pharmacodynamics: Robust expansion (peak at 10 days) and durable B-cell depletion through month 12.
Guidance, Outlook, and Risks
Future Plans
- Next Trial: The Company expects to initiate a randomized pivotal trial of LYL314 in the 2L setting by early 2026.
- Manufacturing: Clinical supply is manufactured at the LyFE Manufacturing Center in Bothell, Washington. Full capacity is expected to exceed 1,200 doses, supporting clinical needs and potential early commercial launch.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks include:
- Clinical trial results may differ from preliminary data.
- Potential for significant adverse events or toxicities.
- Uncertainty regarding regulatory approval.
- Complexity of manufacturing cellular therapies.
- Macroeconomic conditions and general economic risks.
Investor Verification Checklist
- Clinical Endpoints: Verify the definition of "efficacy-evaluable" and the specific criteria for Complete Response (CR) used in the PiNACLE trial.
- Safety Data: Review the full safety profile for Grade ≥ 3 ICANS events, noting the 14% incidence rate in the total cohort.
- Manufacturing Capacity: Confirm the timeline for reaching full staffing and capacity at the LyFE Manufacturing Center to support the projected 2026 pivotal trial.
- Financial Impact: Consult the most recent Form 10-Q (filed May 13, 2025) for cash runway and burn rate, as this 8-K does not contain financial data.
- Regulatory Path: Monitor for updates on the FDA's feedback regarding the transition from the single-arm pivotal trial to the planned randomized pivotal trial.